Jundishapur Journal of Microbiology

Published by: Kowsar

Design of a Universal Influenza A Vaccine Candidate Based on M2e.FliC; Immunoinformatics Analysis, Protein Modeling, and Its Expression in Escherichia coli

Seyed Mostafa Jalili Kolour 1 , Farida Behzadian 1 , * , Behrokh Farahmand 2 and Salimeh Raeisi 1
Authors Information
1 Faculty of Science and Biotechnology, Malek Ashtar University of Technology, Tehran, Iran
2 Influenza Research Lab, Department of Virology, Pasteur Institute of Iran, Tehran, Iran
Article information
  • Jundishapur Journal of Microbiology: November 2018, 11 (11); e66592
  • Published Online: October 28, 2018
  • Article Type: Research Article
  • Received: January 22, 2018
  • Revised: September 18, 2018
  • Accepted: September 20, 2018
  • DOI: 10.5812/jjm.66592

To Cite: Jalili Kolour S M, Behzadian F, Farahmand B, Raeisi S. Design of a Universal Influenza A Vaccine Candidate Based on M2e.FliC; Immunoinformatics Analysis, Protein Modeling, and Its Expression in Escherichia coli, Jundishapur J Microbiol. 2018 ; 11(11):e66592. doi: 10.5812/jjm.66592.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson MA. Influenza cost and cost-effectiveness studies globally: A review. Vaccine. 2013;31(46):5339-48. doi: 10.1016/j.vaccine.2013.09.013. [PubMed: 24055351].
  • 2. Banerjee N, Mukhopadhyay S. Viral glycoproteins: Biological role and application in diagnosis. Virusdisease. 2016;27(1):1-11. doi: 10.1007/s13337-015-0293-5. [PubMed: 26925438]. [PubMed Central: PMC4758313].
  • 3. Baker SF, Nogales A, Finch C, Tuffy KM, Domm W, Perez DR, et al. Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J Virol. 2014;88(18):10778-91. doi: 10.1128/JVI.01440-14. [PubMed: 25008914]. [PubMed Central: PMC4178878].
  • 4. Carrat F, Flahault A. Influenza vaccine: The challenge of antigenic drift. Vaccine. 2007;25(39-40):6852-62. doi: 10.1016/j.vaccine.2007.07.027. [PubMed: 17719149].
  • 5. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007;7(4):267-78. doi: 10.1038/nri2054. [PubMed: 17363960].
  • 6. Ebrahimi SM, Tebianian M. Influenza A viruses: Why focusing on M2e-based universal vaccines. Virus Genes. 2011;42(1):1-8. doi: 10.1007/s11262-010-0547-7. [PubMed: 21082230].
  • 7. Kolpe A, Schepens B, Fiers W, Saelens X. M2-based influenza vaccines: Recent advances and clinical potential. Expert Rev Vaccines. 2017;16(2):123-36. doi: 10.1080/14760584.2017.1240041. [PubMed: 27653543].
  • 8. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, et al. Universal influenza A vaccine: Optimization of M2-based constructs. Virology. 2005;337(1):149-61. doi: 10.1016/j.virol.2005.04.004. [PubMed: 15914228].
  • 9. Lee YT, Kim KH, Ko EJ, Lee YN, Kim MC, Kwon YM, et al. New vaccines against influenza virus. Clin Exp Vaccine Res. 2014;3(1):12-28. doi: 10.7774/cevr.2014.3.1.12. [PubMed: 24427759]. [PubMed Central: PMC3890446].
  • 10. Cho KJ, Schepens B, Seok JH, Kim S, Roose K, Lee JH, et al. Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. J Virol. 2015;89(7):3700-11. doi: 10.1128/JVI.02576-14. [PubMed: 25609808]. [PubMed Central: PMC4403401].
  • 11. Deng L, Cho KJ, Fiers W, Saelens X. M2e-based universal influenza A vaccines. Vaccines (Basel). 2015;3(1):105-36. doi: 10.3390/vaccines3010105. [PubMed: 26344949]. [PubMed Central: PMC4494237].
  • 12. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, et al. M2e-based universal influenza A vaccine. Vaccine. 2009;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. [PubMed: 19840661].
  • 13. Zhang X, Liu M, Liu C, Du J, Shi W, Sun E, et al. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens. Intervirology. 2011;54(5):290-9. doi: 10.1159/000319440. [PubMed: 21228535].
  • 14. Zhang J, Fan HY, Zhang Z, Zhang J, Zhang J, Huang JN, et al. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice. Vaccine. 2016;34(5):622-9. doi: 10.1016/j.vaccine.2015.12.039. [PubMed: 26724200].
  • 15. Mardanova ES, Kotlyarov RY, Kuprianov VV, Stepanova LA, Tsybalova LM, Lomonossoff GP, et al. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin. Bioengineered. 2016;7(1):28-32. doi: 10.1080/21655979.2015.1126017. [PubMed: 26710263]. [PubMed Central: PMC4878292].
  • 16. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56:365-94. doi: 10.1146/annurev.bi.56.070187.002053. [PubMed: 3304138].
  • 17. Zhang Q, Wang P, Kim Y, Haste-Andersen P, Beaver J, Bourne PE, et al. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 2008;36(Web Server issue):W513-8. doi: 10.1093/nar/gkn254. [PubMed: 18515843]. [PubMed Central: PMC2447801].
  • 18. Lin K, Simossis VA, Taylor WR, Heringa J. A simple and fast secondary structure prediction method using hidden neural networks. Bioinformatics. 2005;21(2):152-9. doi: 10.1093/bioinformatics/bth487. [PubMed: 15377504].
  • 19. Eswar N, Eramian D, Webb B, Shen MY, Sali A. Protein structure modeling with MODELLER. Methods Mol Biol. 2008;426:145-59. doi: 10.1007/978-1-60327-058-8_8. [PubMed: 18542861].
  • 20. Kallberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, et al. Template-based protein structure modeling using the RaptorX web server. Nat Protoc. 2012;7(8):1511-22. doi: 10.1038/nprot.2012.085. [PubMed: 22814390]. [PubMed Central: PMC4730388].
  • 21. Kallberg M, Margaryan G, Wang S, Ma J, Xu J. RaptorX server: A resource for template-based protein structure modeling. Methods Mol Biol. 2014;1137:17-27. doi: 10.1007/978-1-4939-0366-5_2. [PubMed: 24573471].
  • 22. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015;10(6):845-58. doi: 10.1038/nprot.2015.053. [PubMed: 25950237]. [PubMed Central: PMC5298202].
  • 23. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37(Database issue):D1006-12. doi: 10.1093/nar/gkn838. [PubMed: 18978023]. [PubMed Central: PMC2686541].
  • 24. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: Preclinical and clinical developments. Expert Rev Vaccines. 2009;8(4):499-508. doi: 10.1586/erv.09.6. [PubMed: 19348565]. [PubMed Central: PMC2706389].
  • 25. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2008;26(2):201-14. doi: 10.1016/j.vaccine.2007.10.062. [PubMed: 18063235].
  • 26. De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londono-Arcila P, et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine. 2008;26(51):6503-7. doi: 10.1016/j.vaccine.2008.09.038. [PubMed: 18835315].
  • 27. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine. 2008;26(27-28):3395-403. doi: 10.1016/j.vaccine.2008.04.052. [PubMed: 18511159].
  • 28. Ebrahimi SM, Tebianian M, Toghyani H, Memarnejadian A, Attaran HR. Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. Protein Expr Purif. 2010;70(1):7-12. doi: 10.1016/j.pep.2009.11.001. [PubMed: 19897044].
  • 29. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011;29(32):5145-52. doi: 10.1016/j.vaccine.2011.05.041. [PubMed: 21624416].
  • 30. Qian F, Guo A, Li M, Liu W, Pan Z, Jiang L, et al. Salmonella flagellin is a potent carrier-adjuvant for peptide conjugate to induce peptide-specific antibody response in mice. Vaccine. 2015;33(17):2038-44. doi: 10.1016/j.vaccine.2015.03.006. [PubMed: 25765964].
  • 31. Balzer S, Kucharova V, Megerle J, Lale R, Brautaset T, Valla S. A comparative analysis of the properties of regulated promoter systems commonly used for recombinant gene expression in Escherichia coli. Microb Cell Fact. 2013;12:26. doi: 10.1186/1475-2859-12-26. [PubMed: 23506076]. [PubMed Central: PMC3621392].
  • 32. Moeini S, Behzadian F, Farahmand B. Construction of chimeric protein 3M2e.FliC and its immunoinformatics analyses and expression in Bacillus subtilis. Vaccine Res. 2016;3(7):12-7. doi: 10.18869/acadpub.vacres.3.7.12.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments